BR112022015977A2 - Anticorpos anti-axl e composições - Google Patents

Anticorpos anti-axl e composições

Info

Publication number
BR112022015977A2
BR112022015977A2 BR112022015977A BR112022015977A BR112022015977A2 BR 112022015977 A2 BR112022015977 A2 BR 112022015977A2 BR 112022015977 A BR112022015977 A BR 112022015977A BR 112022015977 A BR112022015977 A BR 112022015977A BR 112022015977 A2 BR112022015977 A2 BR 112022015977A2
Authority
BR
Brazil
Prior art keywords
compositions
axl antibodies
axl
antibodies
diseases
Prior art date
Application number
BR112022015977A
Other languages
English (en)
Inventor
Gjetting Torben
Lindsted Trine
Willer Anton
Worsaae Anne
Maria Carlsen Melander Eva
Schou Jakobsen Janus
Westh Hansen Randi
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of BR112022015977A2 publication Critical patent/BR112022015977A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

ANTICORPOS ANTI-AXL E COMPOSIÇÕES. A presente invenção refere-se a anticorpos anti-AXL e métodos para usá-los no tratamento de doenças e condições relacionadas à atividade de AXL, por exemplo, câncer.
BR112022015977A 2020-02-28 2021-02-26 Anticorpos anti-axl e composições BR112022015977A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062982852P 2020-02-28 2020-02-28
PCT/IB2021/051636 WO2021171257A1 (en) 2020-02-28 2021-02-26 Anti-axl antibodies and compositions

Publications (1)

Publication Number Publication Date
BR112022015977A2 true BR112022015977A2 (pt) 2022-10-11

Family

ID=75426640

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015977A BR112022015977A2 (pt) 2020-02-28 2021-02-26 Anticorpos anti-axl e composições

Country Status (16)

Country Link
US (1) US11807688B2 (pt)
EP (1) EP4110824A1 (pt)
JP (1) JP2023515821A (pt)
KR (1) KR20220148237A (pt)
CN (1) CN115210263A (pt)
AR (1) AR121441A1 (pt)
AU (1) AU2021225490A1 (pt)
BR (1) BR112022015977A2 (pt)
CA (1) CA3170975A1 (pt)
CL (1) CL2022002259A1 (pt)
CO (1) CO2022012159A2 (pt)
IL (1) IL295596A (pt)
MX (1) MX2022010670A (pt)
PE (1) PE20221783A1 (pt)
TW (1) TW202146455A (pt)
WO (1) WO2021171257A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
BRPI0820543A2 (pt) 2007-11-15 2015-06-16 Chugai Pharmaceutical Co Ltd Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo
RU2577986C2 (ru) 2010-06-18 2016-03-20 Дженентек, Инк. Антитела против axl и способы их применения
MX2017007941A (es) 2014-12-18 2018-01-30 Bergenbio Asa Anticuerpos antagonistas anti-axl.
JP6892431B2 (ja) * 2015-07-10 2021-06-23 ゲンマブ エー／エス 癌治療用のａｘｌ特異的抗体−薬物コンジュゲート
GB201610902D0 (en) * 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
EP3774904A1 (en) * 2018-04-10 2021-02-17 Genmab A/S Axl-specific antibodies for cancer treatment

Also Published As

Publication number Publication date
PE20221783A1 (es) 2022-11-16
TW202146455A (zh) 2021-12-16
WO2021171257A1 (en) 2021-09-02
MX2022010670A (es) 2022-09-23
AR121441A1 (es) 2022-06-08
CN115210263A (zh) 2022-10-18
JP2023515821A (ja) 2023-04-14
CA3170975A1 (en) 2021-09-02
CL2022002259A1 (es) 2023-04-14
IL295596A (en) 2022-10-01
US20210269532A1 (en) 2021-09-02
EP4110824A1 (en) 2023-01-04
US11807688B2 (en) 2023-11-07
KR20220148237A (ko) 2022-11-04
CO2022012159A2 (es) 2022-10-31
AU2021225490A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
BR112019006876A2 (pt) anticorpos e composições anti-lag-3
BR112022003956A2 (pt) Anticorpos anti-cd73
BR112018006257A2 (pt) anticorpos anti-pd-1 e composições
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
BR112018072986A2 (pt) anticorpos anti-pd-1 e anti-lag3 para tratamento de câncer
GT201200318A (es) Anticuerpos hacia gdf8 humano
MX2019010848A (es) Composiciones y procedimientos para el tratamiento del cancer.
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
BR112022015416A2 (pt) Anticorpos anti-ror1 e composições
BR112019023990A2 (pt) Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
BR112015023086A2 (pt) anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira, métodos para produção de um anticorpo anti-cd25 ou fragmento ligante anti cd25, para prevenção de rejeição de órgãos transplantados e para tratamento de uma doença.
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
AR114129A1 (es) ANTICUERPOS TERAPÉUTICOS DIRIGIDOS CONTRA sPLA2-GIB Y SUS USOS
BR112021011729A2 (pt) Tubulisinas e conjugados de proteína-tubulisina
MX2020012107A (es) Composiciones y procedimientos para el tratamiento del cancer.
CO2022019161A2 (es) Tubulisinas y conjugados de proteína-tubulisina
BR112022015977A2 (pt) Anticorpos anti-axl e composições
ECSP22004680A (es) Anticuerpos anti-angpt2
CL2022000294A1 (es) Composiciones biofarmacéuticas y procedimientos conexos.
BR112022024988A2 (pt) Compostos e métodos para tratamento de infecções fúngicas
BR112022013566A2 (pt) Compostos para distúrbios crônicos
BR112021018611A2 (pt) Anticorpos tendo especificidade para btn2 e usos dos mesmos

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LES LABORATOIRES SERVIER (FR)